Table 2.
Characteristics of eligible patients by wound complication status.
| No Wound Complication (column %) (n=50) | Wound Complication (column %) (n=35) | |
|---|---|---|
| Treatment | ||
| Dose Finding (RT + chemo + pazopanib) | 5 (10.00) | 2 (5.71) |
| Dose Finding (RT + pazopanib) | 4 (8.00) | 9 (25.71) |
| Regimen A (RT + chemo + pazopanib) | 17 (34.00) | 17 (48.57) |
| Regimen B (RT + chemo) | 18 (36.00) | 5 (14.29) |
| Regimen C (RT + pazopanib) | 3 (6.00) | 1 (2.86) |
| Regimen D (RT) | 3 (6.00) | 1 (2.86) |
| Age | ||
| Median (range) | 24.69 (5.87–74.66) | 21.37 (5.77–66.48) |
| < 18 years | 17(34.00) | 12(34.29) |
| ≥ 18 years | 33(66.00) | 23(65.71) |
| Sex | ||
| Male | 26 (52.00) | 19(54.29) |
| Female | 24 (48.00) | 16 (45.29) |
| Tumor size (cm) | ||
| Median (range) | 9.1 (4.20–32.60) | 9.7 (3.60–20.60) |
| Primary site | ||
| Extremity | 44 (88.00) | 33 (94.29) |
| Lower Extremity | 30 (60.00) | 31 (88.00) |
| Upper Extremity | 14 (28.00) | 2 (6.00) |
| Trunk | 6 (12.00) | 2 (5.72) |
| T Stage | ||
| T2a | 5 (10.00) | 4 (11.43) |
| T2b | 38 (76.00) | 27 (77.14) |
| Tx | 7 (14.00) | 2 (5.71) |
| Unknown | 0 | 2 (5.71) |
| N Stage | ||
| N1 | 4 (8.00) | 4 (11.43) |
| N0 | 36 (72.00) | 27 (77.14) |
| Nx | 10 (20.00) | 4 (11.43) |
| Metastases* | ||
| None | 41 (82.00) | 25 (71.43) |
| Lung only | 4 (8.00) | 8 (22.86) |
| Other | 5 (10.00) | 2 (5.71) |
| Histology | ||
| Synovial sarcoma | 20 (40.00) | 17 (48.57) |
| Undifferentiated pleomorphic sarcoma | 11 (22.00) | 8 (22.86) |
| Embryonal sarcoma of the liver | 2 (4.00) | 0 |
| Leiomyosarcoma | 2 (4.00) | 2 (5.71) |
| Other | 15 (30.00) | 8 (22.86) |
RT = radiation therapy, chemo = chemotherapy